logo

Diseases and Drugs

Share

collage jan27 As we move into the shortest month of the year, let's take a look at some of the regulatory news reported during January and look ahead to what's in store for February.

ferringpharma dec27 As we wrap up the year, and head into 2023, it's time to take a look at the biotech stocks facing FDA decision in January 2023.

proventionbio nove25 The FDA, which started 2022, on a slow note, has so far approved 30 novel drugs, compared to 47 that were approved during the same period last year. Now, let's take a look at the biotech stocks facing FDA decision in December.

fda oct26 The federal data from the 2022 National Youth Tobacco Survey (NYTS) on E-cigarette use among U.S. youth, released on October 6, presents some grim findings. According to the Morbidity & Mortality Weekly Report, more than 2.5 million U.S. youth currently use E-cigarettes.

monkeypox sept30 As we enter the final quarter of the year, let's take a look at some of the regulatory news that made headlines in September and look ahead to what's in store in October.

zyntegloenhertufda aug26 The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. Now, let's take a look at the biotech stocks facing FDA decision in September.

fda jun24 On July 13, the FDA will decide whether or not to approve Regeneron Pharmaceuticals Inc.'s (REGN) REGEN-COV, proposed for the treatment of COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.

prevnar jun08 On this day last year, i.e., June 8, 2021, the FDA approved Pfizer Inc.'s (PFE) Prevnar 20 vaccine to prevent pneumonia and invasive disease caused by 20 types of pneumococcal bacteria in adults 18 years of age and older.

bavarian nordic 052722 As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June.

fda aprl27 The FDA decision on Amicus Therapeutics' (FOLD) New Drug Application for Miglustat, one of the two components of AT-GAA, proposed for adult patients with Pompe disease, is slated for May 29.

fda march28 An FDA panel is scheduled to review TG Therapeutics Inc.'s (TGTX) Biologics License Application/supplemental New Drug Application for the combination of Ublituximab and Ukoniq, known as the U2 regimen, on April 22, 2022. The U2 regimen is proposed for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

fda feb25 As another month comes to an end, it's time to take a look back at some of the regulatory news that made headlines in February and look ahead to what the month of March has in store.

Follow RTT